Dr. Estela Rodriguez
@Latinamd
Associate Director Community Outreach- 🫁Thoracic Oncology, University of Miami @SylvesterCancer , 🇵🇷Boricua, Co-founder @KidsHelpingKidsSucceed
Look! The @The_Right_Dose survey was featured at #HarvardBreastCancerCourse by @antgiorda—thanks for highlighting dosing in your Phase 1 trials talk! Anne Loeser was the brains and engine behind this work, and the whole team played an integral role: therightdose.org/about-us#team
“Research that is stopped rarely gets going again”- @eaonc Protect public funding for biomedical research and investment in the cures of tomorrow👇🏽👇🏽👇🏽👇🏽
Read more from our co-chairs on the importance of protecting public support for biomedical research: bit.ly/3IvxNQD #CancerResearch #ClinicalTrials
#FLAURA2 Catching up with the press release medical literature. Chemo+osimertinib for 1L EGFR+ NSLC now has OS advantage over osi monotherapy. ➡️Magnitude of OS benefit not reported yet , PFS 29.4 vs 19.9mo (HR 0.75) ➡️ Who gets chemo+tki vs amivantamab+TKI is the ?? ➡️ Weigh…
In this episode of the @IASLC podcast, Lung Cancer Considered, I discuss recently approved sunvozertinib for #EGFR NSCLC with an exon 20 insertion with Dr. James Yang and Dr. @MariamAlex26. Download wherever you get your podcasts or link below! iaslc.org/iaslc-news/lun…
Update to the @ASCO Living Guidelines for NSCLC without a driver alteration @JCO_ASCO from @dwightowenmd et al includes discussion on ivonescimab, the PD-1 / VEGF bispecific antibody, and the HARMONi-2 trial. Promising results but awaiting more data. ascopubs.org/doi/10.1200/JC…
Useful @CACancerJournal review to understand role of Multicancer detection tests for #cancerscreening in clinic and risks/benefits.
Multicancer detection (MCD) tests offer the potential for detecting cancer at early stages and increase screening adherence. This #OpenAccess review led by @theNCI researchers examines the unquantified benefits and harms of MCD tests. acsjournals.onlinelibrary.wiley.com/doi/full/10.33… @OncoAlert
Great question about #ASCOGuidelines in #mesothelioma : should #bevacizumab be offered for pts w mesothelioma age>75? —I think risks overweight benefits for many and we have better treatments today as opposed to when this cisplatin/pem/bev trial was published (MAPS trial (2016)…
Curiosity question from my thoracic colleagues: why in the ASCO Guideline for mesothelioma is there an age cut off for consideration of use of avastin?
Thanks @dougflora2 for this spectacular episode. We discuss ✅how AI could make healthcare more humane ✅how physicians are aiming for training in AI/ dual certification in clinical informatics ✅role of ACCC I love how Dr Flora says- “don’t compare your first chapter to…
🪄Empowering Oncologists: Evolving role of AI in Oncology In this episode, host Dr. Jasmine Kamboj (@JasmineKambojMD) is joined by Dr. Douglas Flora (@dougflora2), Executive Medical Director at the Yung Family Cancer Center, St. Elizabeth Healthcare (@StElizabethNKY). Dr. Flora…
Geriatric oncology has made great strides in improving outcomes for older adults with cancer. In a 2024 #OpenAccess review, @rochgerionc et al discuss the why, what, and how of geriatric assessment for clinicians. Revisit it here: acsjournals.onlinelibrary.wiley.com/doi/full/10.33… @oncoalert #GeriOnc
Great opportunity to share your own personal story for @JCO_ASCO #ArtofOncology
Hot off the presses! Tips from the editorial board @JCO_ASCO @ASCO on what we're looking for in narrative medicine or poetry pieces for the Journal of Clinical Oncology! The Art of the Art of Oncology | @DrSGraff @SylvesterCancer @UMiamiHealth ascopubs.org/doi/10.1200/JC…
☀️Great Lunch with the Leader with @DrSDNimer this week visiting the expanded State-of-the-Art radiation facilities of our @SylvesterCancer Broward satellite in Plantation and excited to meet the amazing team bringing multi-D care and clinical trials closer to where patients…
🔥Off the press: @ASCO #LivingGuidelines for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2025.1 | 👉🏽 ascopubs.org/doi/10.1200/JC… ✅ Clear algorithm for first and second line options ✅ Review of recent data:…
Excited to be Guest Editor ✍️ for this special @Cancers_MDPI issue on Advances in NSCLC 🫁Therapy & Prognostic 🧬Prediction with @HemOncMiami @SylvesterCancer Chief fellow @Jani_Chinmay 👇🏽👇🏽👇🏽submit your manuscripts by 2/26/28 #lcsm @HemOncFellows
📢We're Excited to share the #SpecialIssue "#Lung #Cancer—Advances in #Therapy and Prognostic Prediction" edited by Dr. Chinmay T. Jani and Dr. Estela Rodriguez, now open for submissions! 👏 🗓️Submission Deadline: 28 February 2026 📌Find more details here: mdpi.com/journal/cancer…
¿Estás interesado en los avances más recientes en la investigación y manejo del cáncer de pulmón? No pierdas la oportunidad de aprender del Dr. Luis Corrales, una eminencia en la oncología. El Dr. Corrales es Oncólogo Médico de la Universidad de Costa Rica, con especialización…
Join us at the @FLASCO_ORG Fall Meeting - Oct 23-25 with great updates on general oncology and opportunities for research collaborations & networking @ASCO
FLASCO Fall Oncology Congress registration NOW OPEN!
👨🏫 As Academic Chief fellow, I’m excited to launch our new #HemeOnc Bootcamp for fellows! Over the next few weeks, we’ll cover essential hematology & oncology topics - focused, guideline-based, and packed with 101s to build strong foundations. Let the learning begin! 📚🩸🎯…
🚀 Kickstarting the first didactics of the new academic year with our Oncology Bootcamp! This year’s Bootcamp will span the first two months, focusing on case-based, guideline-driven discussions across solid and liquid tumors.! #MedTwitter @Jani_Chinmay